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Sphingolipids act as signaling mediators that regulate a diverse range of cellular events. 
Although numerous sphingolipid functions have been studied, little is known about the effect 
of sphingolipids on monocyte differentiation into macrophages. Here, we report that two 
lysosphingolipids, sphingosylphosphorylcholine (SPC) and lysosulfatide (LSF), inversely 
affect macrophagic differentiation of monocytic cell lines, U937 and THP-1. Molecular 
analyses revealed that SPC enhances, whereas LSF suppresses, phorbol ester-induced 
classical (M1-polarized) differentiation to macrophages. The expression of CD11b, a 
macrophage marker, was induced in accordance with the activation status of the 
Raf/MEK/ERK signaling pathway in which SPC and LSF had opposite effects. 
Pharmacological inhibition of this pathway aborted the differentiation, indicating that this 
signaling pathway is required. Consistently, SPC promoted, while LSF inhibited, monocyte 
adhesion to fibronectin, through the phosphatidylinositol-3-kinase (PI3K)/Akt signaling 
pathway. The effects of SPC on Raf/MEK/ERK and PI3K/Akt signaling were dependent on 
Gi/o, whereas the SPC-induced calcium influx was dependent on Gq. Thus SPC utilizes 
G-protein coupled receptor. In contrast, the effects of LSF were independent of Gi/o and Gq. 
These results suggest that SPC enhances, whereas LSF suppresses, monocyte differentiation 
into macrophages through regulating the Raf/MEK/ERK and PI3K/Akt signaling pathways 
via distinct mechanisms. 
 
1.1 Keywords 






     Sphingolipids, which consist of a long-chain hydrophobic tail and a polar head group, are 
essential components of cellular membranes or membrane microdomain [1]. In addition to 
their function as components, recent studies have revealed that sphingolipids could be 
employed as signaling mediators, regulating diverse cellular events that include proliferation, 
migration, adhesion, and differentiation. Therefore, sphingolipids, such as ceramide, 
sphingosine, sphingosine-1-phosphate (S1P), ceramide-1-phosphate, and 
sphingosylphosphorylcholine (SPC), are regarded as “bioactive lipids” [2]. However, 
activities of sphingolipids are not uniform; some sphingolipids actually mediate opposite 
consequences in the cells. For example, sphingosine and ceramide induce apoptosis [3,4] 
whereas S1P promotes cell survival [5]. These cellular effects may be transmitted by receptor 
molecules. S1P is a ligand for the G-protein-coupled receptors (GPCR) S1P1–5 and S1P 
promotes cell adhesion and cell migration via S1P receptors [6,7]. However, not all bioactive 
sphingolipids have authentic receptors.  
     In addition to studies on the cellular level, the function of sphingolipid(s) in animal model 
has been examined using ISP-1/myriocin, an inhibitor for biosynthesis of sphingolipids [8]. 
ISP-1/myriocin administered to apolipoprotein E-deficient mice, a widely used animal model 
for atherosclerosis, caused a decrease in plasma sphingolipid levels and a reduction in 
atherosclerosis area [9]. Therefore, expression of sphingolipid(s) could be required for the 
progression of atherosclerosis, although the molecular species involved in this model is 
currently not identified. Monocyte-derived and classically activated (M1 polarized) 
macrophages have essential roles in the progression of atherosclerosis [10]. Circulating blood 
monocytes differentiate into macrophages in various tissues in the course of reaching the cell 
periphery, and thus correct monocytic differentiation to macrophages is an important step for 
appropriate immune function [11]. Recent studies have shown that S1P regulates lymphocyte 
trafficking [12,13]. Furthermore, studies have suggested that lipid species such as 
lysophosphatidic acid (LPA) or S1P enhance integrin-mediated B lymphocyte adhesion 
through G-proteins, analogous to the activities of chemokines [14,15]. Therefore, we 
postulated that sphingolipids may regulate monocyte differentiation into macrophages. 
     Several studies have reported that the phorbol ester, 12-O-tetradecanoylphorbol 13-acetate 
(TPA), could trigger monocyte differentiation into M1 macrophages through activating 
protein kinase C in monocytic cell lines [16,17]. In the present study, we found that two 
lyosphingolipid species, SPC and lysosulfatide (LSF), have inverse regulatory effects on 
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TPA-triggered cellular adhesion and macrophagic differentiation of monocytic cell lines, 
U937 and THP-1 cells. Molecular targets for the regulatory effect of these sphingolipids 
(SPC to promote and LSF to inhibit) involve the regulation of the Raf/MEK/ERK and 








SPC, fibronectin, and fatty acid-free BSA were purchased from Sigma (St. Louis, MO). 
1-Oleoyl-sn-glycero-3-phosphate (LPA) and S1P were obtained from Cayman Chemical Co. 
(Ann Arbor, MI). All other lipids were from Matreya (Pleasant Gap, PA). 
12-O-Tetradecanoylphorbol 13-acetate (TPA), PD98509, and LY294002 were obtained from 
Calbiochem (San Diego, CA) and pertussis toxin (PTX) was purchased from Seikagaku 





We used the following antibodies: a rabbit monoclonal antibody against phospho-Raf-1 
(Ser338) and rabbit polyclonal antibodies against phospho-ERK1/2 (Thr202/Tyr204), 
ERK1/2, phospho-MEK1/2 (Ser217/221), MEK1/2, phospho-Akt (Ser473), and Akt (Cell 
Signaling Technology, Beverly, MA); rabbit polyclonal antibodies against Raf-1 (Santa Cruz 
Biotechnology, Santa Cruz, CA); a mouse monoclonal antibody against CD11b/Mac1 
(ICRF44) and a fluorescein isothiocyanate (FITC)-conjugated rat anti-mouse IgG1 (BD 
Pharmingen, San Diego, CA); a mouse monoclonal antibody against CD206/ macrophage 
mannose receptor (15-2) (AbD Serotec, Kindlington); and a horseradish peroxidase 
(HRP)-conjugated goat anti-rabbit IgG (Zymed Laboratories, South San Francisco, CA). 
 
 3.3 Cell culture 
 
U937 human monocytic cells and THP-1 human monocytic cells were obtained from the 
American Type Culture Collection (Manassas, VA) and the European Collection of Cell 
Cultures (Salisbury, Wiltshire, UK), respectively. U937 cells and THP-1 cells were cultured 
in RPMI1640-HEPES medium (Nacalai Tesque, Kyoto, Japan) supplemented with 10% fetal 
bovine serum (FBS) (JRH, Lenexa, KS), sodium pyruvate (Invitrogen, Carlsbad, CA), 
nonessential amino acids (Invitrogen), and 2-mercaptoethanol (Nacalai Tesque). Serum 
starvation was carried out in the RPMI1640 containing 0.25% fatty acid-free BSA overnight. 
The Plat-A cells and Plat-E cells were kindly provided by Dr. Toshio Kitamura (University of 
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Tokyo, Tokyo, Japan). Plat-A cells and Plat-E cells were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM) (Nacalai Tesque) supplemented with 10% FBS [18]. RH7777 cells 
stably expressing LPA2 (LPA2 cells) were a generous gift from Dr. Fumikazu Okajima 
(Gunma University, Gunma, Japan) and were characterized previously [19]. LPA2 cells were 
maintained in !-MEM (Nacalai Tesque) supplemented with 10% FBS and 250 !g/ml G418. 
 
3.4 Cell adhesion assay 
 
To assess the effect of LSF and SPC on cellular adhesion to fibronectin, 96-well 
flat-bottomed plates were coated with 50 !l fibronectin (10 !g/ml) overnight at 4ºC and 
blocked with 100 !l 0.5% BSA in phosphate-buffered saline (PBS) for at least 1 h at 37ºC. 
U937 cells (1 " 10
6
 cells/ml) in RPMI1640 containing 0.25% BSA were stimulated with LSF 
or SPC for 1 h at 37ºC in the fibronectin-coated 96-wells plates. XTT assay was carried out to 
monitor adherent cells.  
 
3.5 Flow cytometry 
 
U937 cells (1 " 10
5
 cells/ml) and THP-1 cells (2 " 10
5
 cells/ml) were incubated in the 
presence or absence of S1P (1 !M), LSF (5 !M), or SPC (10 !M) for 16 h, followed by 
treatment with or without TPA (1 ng/ml) for 72 h. Unless stated, medium contained FBS to 
support cell growth. In some experiments, medium was supplied with FBS that was 
pretreated with charcoal so that some of the content such as lipids was depleted. To determine 
whether SPC enhances TPA-induced differentiation through the Raf/MEK/ERK or PI3K 
signaling pathway, cells were pretreated with or without PD98059 (50 !M), LY294002 (2 
!M) for 15 min prior to the SPC stimulation. The cells were washed with PBS once and 
resuspended in fluorescence-activated cell sorter buffer (1% FBS and 0.1% NaN3 in PBS). 
Cells were incubated with anti-CD11b/Mac-1 antibody or CD206 antibody for 45 min at 
room temperature. Cells were then labeled with FITC-conjugated rat anti-mouse IgG1 for 30 
min at room temperature. Data were acquired using a FACScan (BD Biosciences, Franklin 
Lakes, NJ) instrument and analyzed using FlowJo software (Tree Star, San Carlos, CA). 
 
 3.6 RT-PCR 
 
Total RNAs were prepared (RNeasy Mini; Qiagen, Valencia, CA) and reverse transcribed. 
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First strand cDNA was subjected to PCR in which various buffer, annealing temperatures and 
cycles were optimized to ensure template dose-dependent amplification. The primer pairs 
used were as follows: IL12B (212 bp), 5’-TGTCTGCCAGGATGTATGGA-3’, 
5'-TATCTCTTGCGTTCCCATCC-3’; IL10 (293 bp), 
5’-TTACCTGGAGGAGGTGATGC-3’, 5'-ATAGAGTCGCCACCCTGATG-3’; IL6 (208 
bp), 5’-AGTTCCTGCAGAAAAAGGCA-3’, 5'-AACAACAATCTGAGGTGCCC-3’; 
TGFB1 (361 bp), 5’-GCCACAGATCCCCTATTCAA-3’, 
5'-TCTTGCAGGTGGATAGTCCC-3’; FCER2 (272 bp), 
5’-TCAGGACTTGGAGCTGTCCT-3’, 5'-CCATGTCGTCACAGGCATAC-3’; G3PDH 
(983 bp), 5’-TGAAGGTCGGAGTCAACGGATTTGGT-3’, 
5'-CATGTGGGCCATGAGGTCCACCAC-3’; G#q-I (214bp), 
5’-ATGGCTTACCCATACGACGT-3’, 5’-CCAGATTGTACTCCTTCAGG-3’. 
 
3.7 Western blotting 
 
To test the inhibitory effect of LSF on the Raf/MEK/ERK and PI3K/Akt signaling pathways, 
U937 cells and THP-1 cells (5 " 10
5
 cells/ml) were incubated with LSF for 16 h, and then 
stimulated with TPA (1 ng/ml) for 5 min. To test the stimulatory effect of SPC or S1P on the 
Raf/MEK/ERK and PI3K/Akt signaling pathways, serum-starved cells (1 " 10
6
 cells/ml) 
were stimulated with SPC (10 !M) or S1P (1 !M) for the indicated time. Cells were washed 
once with ice-cold PBS and lysed with ice-cold cell lysis buffer [10 mM Tris-HCl (pH 7.4), 
150 mM NaCl, 1 mM EDTA, 1% Triton-X100, protease inhibitor cocktail (Nacalai Tesque)]. 
The chemiluminescence signal was detected using a HRP substrate (Chemi-Lumi One; 
Nacalai Tesque) and a Luminoimage Analyzer LAS-3000 (Fujifilm, Tokyo, Japan). 
 
3.8 Retrovirus infection 
 
The receptor-G!q interaction-blocking “mini gene” (G!q-I), which corresponds to the 
C-terminal peptide sequence of G!q residues 305–359, subcloned into pcDNA3, was a kind 
gift from Dr. Jun Takasaki (Astellas Pharma Inc., Tokyo, Japan) [20]. G!q-I was subcloned 
into the modified mouse stem cell viral vector pMSCV (Clontech, Mountain View, CA) 
carrying an internal ribosomal entry site (Clontech) and resistance gene for blasticidin 
(Invitrogen). Virus was prepared by transient transfection to Plat-A or Plat-E packaging cells 
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as previously reported [21]. U937 cells (2 " 10
5
 cells/well) were spin-infected (at 32ºC for 90 
min) in 96-well flat-bottomed plates in the presence of polybrene (6 !g/ml). The 
retrovirus-infected cells were selected with blasticidin S (10 !g/ml) (Invivogen, San Diego, 
CA) for 14 days. 
 
3.9 Measurement of intracellular calcium concentration 
 
Serum-starved U937 cells (5 " 10
5
 cells/ml) were loaded with Indo-1 AM (1 !M) (Dojindo, 
Mashiki, Japan) for 30 min at 37ºC. The cells were washed twice with Hanks’ balanced salt 
solution (HBSS; Sigma) and resuspended in HBSS containing calcium chloride at a density 
of 5 " 10
5
 cells/ml. The cell suspension (2.5 ml) was transferred to a quartz cuvette with 
constant stirring and preheated for 5 min at 37ºC in an RF-1500 spectrofluorometer 
(Shimadzu, Kyoto, Japan). Cells were stimulated with S1P (1 !M), LSF (5 !M), or SPC (10 
!M) at 37ºC as indicated. Time-lapse change of emission fluorescence intensity at 405 nm 
and 485 nm was measured upon excitation at 338 nm using an RF-1500. Digitonin was used 
to permeabilize cells and EGTA was employed to trap Ca
2+
 during compensation of emission 
signals. [Ca
2+
]i was calculated using a program pack for intracellular calcium measurement 
for the instrument (Shimadzu). Ca
2+
 influx of LPA2-RH7777 cells infected with 
MSCV-G#q-I was measured by FLIPR Calcium assay 4 kit (Molecular devices) in 
accordance with manufacture’s protocol. In brief, 1.5 " 10
4
 cells were inoculated in 
half-sized black 96-well plate and incubated 4 hr with serum-free medium. After loading with 
fluorescent calcium indicator, LPA (10 !M) was injected in FLEX station II (Molecular 
devices) and time-lapse change in fluorescence (Ex 485 nm, Em 525 nm) was monitored.  
 
3.9 Statistical assessment of data 
 
Data shown on bar graphs are expressed as mean values of replicate in each assay. Values of 
standard error of deviation were indicated with lines on top. Statistical significance between 





4.1 Effect of LSF and SPC on TPA-induced expression of macrophage markers. 
 
Recently, bioactive lipids such as S1P and LPA were proposed to function in the context of 
cellular adhesion events, analogous to chemokines [14,15,22]. We tried to understand the 
involvement of less characterized bioactive sphingolipid species, SPC and LSF in monocytic 
cell differentiation to macrophage. We opted to examine the change of cell surface 
macrophage marker expression upon in vitro differentiation of monocytic cell line U937. 
U937 cells have been utilized to examine macrophagic differentiation of monocytic cells in 
vitro [23]. TPA triggers U937 differentiation into an immature macrophage intermediate state 
rather than mature macrophage-like cells when expression of cell surface receptors was 
examined [24]. TPA is known to induce an increase in the expression of CD11b (integrin #M) 
among differentiation markers [17]. We assessed the expression of CD11b by flow cytometry 
to determine whether these sphingolipids could affect differentiation. In such assay, LSF 
strongly suppressed, but SPC slightly enhanced, the TPA-induced CD11b expression in U937 
cells (Fig. 1A) and THP-1 cells (Fig. 1B), whereas the effect of S1P on CD11b expression 
was inconsistent between the two cell lines although S1P is thought to be important for cell 
adhesion of macrophages[14,15,22]. Since enhancement by SPC was rather subtle in normal 
culture medium, stimulatory effect of SPC was examined in the culture medium containing 
charcoal treated FBS (likely depleting lipid content) for U937 cells. In such medium, TPA 
subtly induced CD11b whereas addition of SPC strongly enhanced the event in U937 cells 
(Fig. 1C). To determine macrophage marker expressed in matured macrophage, mannose 
receptor (CD206) induction was also examined. Only TPA-triggered SPC treated cells 
expressed detectable level of CD206 (Fig. 1C). These data indicated that serum content(s) 
affect the effect of SPC in the differentiation event. When THP-1 cells were examined, TPA 
strongly induced whereas addition of SPC exhibited subtle enhancement in CD11b staining. 
Neither condition induced detectable CD206 expression in THP-1 (Fig. 1C). These results 
were consistent with the previous report indicating that U937 cells more resemble human 
monocytes than THP-1 cells [25]. 
 
  Polarized macrophage differentiation could account for the various biological functions of 
macrophages. Difference in marker expression could indicate the functional difference of 
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macrophage. Differently activated macrophages could be classified into two major groups: 
classical macrophage (M1) or alternative macrophage (M2). The expression of interleukins 
10 and 12 could be used to distinguish M1 and M2 subtypes. M2 macrophages could be 
further defined by the use of IL-6, TGF", and CD23, although some of these markers are also 
expressed in M1 cells [26,27]. We analyzed the gene expressions of these marker proteins by 
RT-PCR in order to determine whether addition of SPC could change macrophage subtype 
from M1 subtype, which is induced by TPA alone. The gene expression profiles for TPA- 
and the TPA plus SPC-induced macrophage were very similar in terms of marker expression, 
in which the induction of IL-10, 12, 6, and CD23 was detected but not TGF" (Fig. 1D). This 
result indicated that SPC enhances the classical M1 macrophage differentiation of monocytic 
cells triggered by TPA. Taken together, these results suggest that LSF could suppress, but 
SPC could enhance, TPA-triggered monocyte differentiation into M1 macrophages.  
 
4.2 Effect of SPC and LSF on the Raf/MEK/ERK signaling pathway. 
 
TPA induces monocyte differentiation into macrophages through activation of the classical 
MAP kinase pathway composed by Raf-1, MEK1/2, and ERK1/2. SPC and S1P were 
reported to induce ERK1/2 phosphorylation in several cell lines, although they are not of 
monocytic origin [28]. Therefore, we tested the effect of LSF, SPC, and S1P on a signaling 
cascade involving Raf-1, MEK1/2, and ERK1/2 in U937 cells. Administration of TPA 
strongly induced the phosphorylation of Raf-1 (Ser 338), MEK1/2 (Ser217/221), and ERK1/2 
(Thr202/Tyr204) (Fig. 2A). LSF inhibited phosphorylation of these proteins regardless of the 
presence of TPA (Fig. 2A). When U937 cells were maintained in normal culture medium 
containing serum, phosphorylation of the cascade was detectable, most likely due to basal 
stimulation from the content of the serum (i.e., growth factors). SPC was added to 
serum-starved U937 cells to reduce the background phosphorylation caused by these serum 
factors. Under such conditions, SPC transiently induced phosphorylation of Raf-1, MEK1/2, 
and ERK1/2 (Fig. 2B). S1P also induced phosphorylation of Raf-1, MEK1/2, and ERK1/2 
(Fig. 2C), although S1P did not enhance monocyte differentiation into macrophages (Fig. 1). 
Consistently, LSF suppressed, but SPC induced, phosphorylation of ERK1/2 in THP-1 cells 
(Supplemental Fig.1 A,B). We next used a MEK-specific inhibitor, PD98059, to address 
whether activation of the Raf/MEK/ERK signaling pathway is required for enhancement of 
TPA-induced CD11b expression by SPC. Indeed, PD98059 inhibited CD11b expression 
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TPA/SPC-treated cells when cultured in medium containing charcoal-treated FBS in 
dose-dependent manner (Fig. 2D). These results suggest that the Raf/MEK/ERK signaling 
pathway plays an important role in TPA-induced monocyte differentiation into macrophages, 
and SPC enhances, but LSF suppresses, this event. The inability of S1P to induce CD11b, 
despite its ability to induce MAP kinase activation, might indicate that MAP kinase 
activation is not sufficient and another signaling pathway also takes part in macrophage 
differentiation. 
 
4.3 Effect of SPC and LSF on the PI3K/Akt signaling pathway. 
 
During monocyte differentiation into macrophages, circulating monocytes attach to the 
endothelial cells, and this is followed by transmigration through the endothelial layer into the 
intima, where monocytes differentiate into macrophages [10]. Integrins are involved in the 
adhesion of circulating monocytes toward endothelial cells, and the initial adhesion is 
dependent on integrins [29]. Therefore, we tested the effect of SPC and LSF on the adhesion 
of U937 cells to fibronectin, which binds to "1 integrins, as a model substrate. SPC enhanced, 
whereas LSF suppressed, the adhesion of U937 cells to fibronectin in the absence of TPA 
(Fig. 3A). Upon exposure to chemokines from inflamed tissues, monocytes trigger 
chemokine receptor signaling, which results in the activation of PI3K to enhance chemotaxis 
or adhesion to endothelial cells [30,31]. Therefore, PI3K activation in SPC-treated U937 cells 
was monitored by measuring hydrophobic motif phosphorylation of Akt. Consistently, SPC 
induced transient Akt phosphorylation at about 5 min after the stimulation (Fig. 3B). We next 
examined the effect of PI3K inactivation on cell adhesion to fibronectin. Pretreatment with 
LY294002, a specific but reversible PI3K inhibitor, attenuated the SPC-induced increase of 
adhesion of U937 cells to fibronectin (Fig. 3C). Less prominent inhibition was found in cells 
treated with PD98059. Concurrent loss of Akt phosphorylation was observed in 
LY294002-treated U937 cells (Fig. 3D). In contrast to SPC, LSF suppressed phosphorylation 
of Akt, regardless of the addition of TPA, which is consistent with the suppression of 
adhesion to fibronectin (Fig. 3E). These results suggest that SPC enhances adhesion of U937 
cells to fibronectin through the PI3K/Akt signaling pathway. We also carried out these signal 
transduction assessments in THP-1 cells. Since obtained results for the response to SPC and 
LSF in THP-1 were similar to that of U937 cells, short term effects of SPC and LSF seemed 
to be universal to monocytic cell lines (Supplemental Fig. 1 A-C). We also tried to assess the 
effect of LY294002 in U937 cell differentiation. However, prolonged exposure to this 
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inhibitor caused cell lethality thus involvement of PI3K in CD11b expression could not be 
tested in the condition in which Akt phosphorylation is completely blocked. This result was 
consistent with the line of evidence that PI3K signaling pathway provide survival signal in 
cancer cells. We therefore titrate down LY294002 to compromise PI3K activity in 
differentiation assay without affecting cell viability. Indeed, cellular lethality was avoided in 
lower concentration (1 or 2 µM) of LY294002. Although inhibitory effect was predicted, 
CD11b induction was dose-dependently stimulated in this condition (Fig. 3F). These results 
indicated that PI3K pathway could work inhibitory to CD11b expression. Alternatively, since 
this concentration of LY294002 may not completely shut down SPC-induced Akt 
phosphorylation, prolonged mild PI3K inhibition may alters unidentified signal transduction 
event(s) other than specific to SPC. 
 
4.4 S1P receptor(s) is not involved in the SPC/LSF response. 
 
SPC enhanced the adhesion of U937 cells to fibronectin, which was very similar to the 
effects of S1P [6]. Moreover, previous data showed that SPC could utilize S1P3, an S1P 
receptor, to induce an influx of calcium and eNOS activation in endothelial cells [32,33]. 
Alternatively, S1P might be delivered from SPC by autotaxin/lysophospholipase D [34,35], 
which is reported to be present in sera and may therefore be present in the FBS supplied in 
the culture medium. To determine whether S1P production was involved in this system, we 
measured cellular calcium influx after lipid stimulation. Both SPC and LSF caused calcium 
influx when administrated to Indo-1-loaded U937 cells (Fig. 4A). The calcium concentration 
peaked around 200 s after stimulation with either LSF or SPC. Maximum calcium 
concentration was higher in SPC-treated cells than in LSF-treated cells. When cells were 
stimulated by S1P, U937 cells also exhibited calcium influx, which reached a peak within 10 
s, and this peak was much sharper than that of SPC or LSF (Fig. 4B). Repeated addition of 
S1P resulted in a lack of calcium influx, indicating that the S1P receptor was desensitized by 
primary stimulation (Fig. 4B). When SPC or LSF was used as secondary stimulant, influx 
caused by these lipids was not affected by S1P pre-desensitization (Fig. 4B). These results 
ruled out the involvement of S1P receptors on intracellular calcium mobilization induced by 
SPC or LSF. When a calcium channel inhibitor (SKF-96365 or 2-APB, 10 #M) was supplied 
to the culture during differentiation, cells underwent massive cell death; thus, any long-term 




 4.5 Involvement of Gi/o proteins in SPC-induced activation of the Raf/MEK/ERK and 
PI3K/Akt signaling pathways. 
 
SPC clearly stimulated cellular signaling, such as MAP kinase and PI3K activation. Thus, we 
focused on the cellular signaling downstream of possible GPCR(s) for SPC. SPC-induced 
ERK1/2 phosphorylation was severely inhibited by pretreatment with PTX, an irreversible 
blocker for Gi/o protein activation (Fig. 5A). Consistently, SPC-induced phosphorylation of 
Akt was also inhibited by PTX, although basal phosphorylation was not affected (Fig. 5A, 
Suppl Fig. 1C). These results suggest that SPC activates the Raf/MEK/ERK and PI3K/Akt 
signaling pathways via Gi/o proteins in U937 cells. In contrast, the inhibitory effect of LSF in 
TPA-mediated activation was not inhibited in the presence of PTX (Fig. 5B). Thus, the mode 
of action between SPC and LSF appeared to be independent. 
 
4.6 Involvement of Gq proteins in SPC-induced intracellular calcium mobilization. 
 
Since both SPC and LSF elicited calcium influx, the possible involvement of Gq proteins was 
predicted. Downstream signaling of Gq proteins can be inhibited by the expression of the 
C-terminal peptide of G!q, which interacts with the intracellular region of agonist-activated 
GPCR, thus competing with endogenous G!q. The peptide was therefore designated as a G!q 
inhibitor (G!q-I), and Gq selective inhibition using this peptide has been reported both in 
vitro and in vivo [20,36]. We introduced G!q-I-IRES-blasticidin to U937 cells with 
retrovirus-mediated gene transfer and a blasticidin S-resistant pool was selected to 
circumvent the cloning effect. We confirmed the expression of G!q-I in semi-quantitative 
RT-PCR, which resulted in a specific expression of G!q-I mini gene (Supplemental Fig. 2). 
In control virus-infected cells (only encoding IRES-blasticidin without G!q-I), both SPC and 
LSF induced consistent calcium influx (Fig. 5C). When G!q-I was introduced, SPC-induced 
calcium influx was partially inhibited. In contrast, LSF-induced calcium influx was not 
inhibited (Fig. 5C). To examine the completeness of inhibition, the effect of G!q-I was 
evaluated in LPA2-overexpressed McA-RH7777 cells, in which LPA2 is coupled to Gq 
proteins [37]. The Gq-mediated calcium influx was attenuated when the inhibitor peptide was 
expressed in this cell line (Fig 5D). These results suggest that SPC and LSF induce calcium 





 5.1 Intracellular signal transduction is involved in the functioning of SPC and LSF. 
 
Previous studies have shown that SPC induces ERK1/2 activation in several cell lines [38], 
although its biological consequences are not clear. In the present study, we showed that SPC 
activated the Raf/MEK/ERK signaling pathway in monocytic cell lines (Figs. 2B and 2D). In 
contrast, LSF suppressed the Raf/MEK/ERK signaling pathway in these same cells (Fig. 2A). 
As reported previously [39], PD98509, a MEK-specific inhibitor, inhibited TPA-induced 
differentiation of U937 cells into macrophages (Fig. 2D). PD98509 also suppressed 
enhancement of TPA-induced macrophagic differentiation by SPC (Fig. 2D). Therefore, the 
Raf/MEK/ERK regulatory activities of these lipids must be important for subsequent 
monocyte differentiation into macrophages. In this study, we also demonstrated that SPC 
promotes, but LSF inhibits, U937 cell adhesion to fibronectin through regulating the 
PI3K/Akt signaling pathway (Fig. 3). Fibronectin binds to "1 integrins, mainly to the !5"1 
integrin as opposed to the !4"1 and !v"1 integrins. When monocytes initially adhere to 
endothelial cells, PI3K and "1 integrins are activated [29,40]. Therefore, SPC and LSF might 
also modulate monocyte adhesion to endothelial cells in the course of monocyte 
differentiation. 
 
5.2 S1P receptors may not be involved in the functioning of SPC and LSF. 
  
SPC and LSF share similar structural features since both are lysosphingolipids composed of a 
long-chain base and a polar head group, in which a phosphocholine and a sulfated galactose 
occupy the head group of SPC and LSF, respectively. Thus, the inverse functions of the lipids 
in the differentiation into macrophages may be explained by the structural difference of the 
polar head groups that can be recognized by distinct receptor(s). Several studies have shown 
that S1P receptors are lower-affinity receptors for SPC [28,41]. Both SPC and LSF have been 
reported to cause calcium influx and Akt phosphorylation via S1P3 in endothelial cells [42]. 
Moreover, SPC was shown to inhibit the generation of reactive oxygen species and MCP-1 
through S1P3 in vascular smooth muscle cells and aorta tissue [32]. Therefore the S1P 
receptors may be one possible cellular target for SPC and LSF. Since we found that both SPC 
and LSF trigger calcium influx, as does S1P in these cell lines, we tested whether S1P 
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receptors are involved in SPC- or LSF signaling pathway in our system. SPC- or 
LSF-induced calcium influx was not affected by desensitization of S1P receptors in U937 
cells (Fig. 4B). Consistently, S1P did not affect TPA-triggered monocyte differentiation into 
macrophages (Fig. 1). Therefore, S1P receptors are unlikely to be involved in the modulation 
of monocyte differentiation by LSF and SPC. 
 
5.3 Possible involvement of proton-sensing receptors in the functioning of SPC and LSF. 
 
Many reports have suggested that SPC is a ligand for OGR1, GPR4, and G2A, all of which 
belong to the OGR1 family of GPCR [37,43,44]. More recently, however, Ludwig et al. 
reported that OGR1 and GPR4 recognize protons as their ligands [45]. Subsequently, other 
OGR1 family receptors, G2A and TDAG8, were shown to have similar characteristics 
[46-48], although the ability of G2A to sense protons requires further confirmation [49]. It 
was reported that among lysosphingolipids, SPC and psychosine antagonize proton-sensing 
receptors [46,50]. Collectively, OGR1 family is now regarded as proton-sensing-GPCR that 
could be antagonized with lysosphingolipids. Indeed, we detected the mRNA expression of 
G2A, OGR1, and TDAG8 in U937 and THP-1 cells by RT-PCR (data not shown). However, 
since SPC and LSF inversely affected the differentiation of monocytic cells into macrophages 
throughout this study, it is difficult to explain the opposite functions of SPC and LSF on 
differentiation through antagonistic effects on the proton-sensing GPCR. With regard to LSF 
function, our results indicated that both PTX and Gq inhibitor had no effect on the cellular 
phenotypes of LSF, indicating that LSF may not use GPCR for its differentiation-inhibitory 
activity; these studies, however, did not conclusively exclude the involvement of 
proton-sensing GPCR. Ideally, further study is needed to determine whether SPC and LSF 
modulate TPA-triggered monocyte differentiation into macrophages via proton-sensing 
GPCRs in the monocytic cell lines U937 and THP-1.  
 
5.4 SPC- or LSF-mediated differential modulation of macrophage production in vivo. 
 
Correct participation of differentiated resident macrophages in various tissues is important for 
both innate and adaptive immunity. Lipid(s) circulating in body fluid or expressed in certain 
tissues can control the function of macrophages [51]. The possibility exists that SPC and LSF 
can modulate intracellular signaling and control monocyte differentiation and cellular 
adhesion in vivo. Nofer et al. reported that S1P, SPC, and LSF are present in high-density 
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lipoprotein (HDL) [42,52,53]. HDL might be one of the major lipid carriers in the serum for 
delivery of (sphingo)lipids to monocytes. Therefore, the lipid content of HDL could mirror 
the lipid species in which monocytes are exposed. On the contrary, Kimura et al. have shown 
that the content of SPC and LSF in HDL as found by Nofer et al. was unlikely high [7]. Other 
than HDL-mediated delivery, expression in the plasma or local expression by endothelial 
cells are candidate production sites for these lipids. Our current findings could have a 
connection to the pathogenesis of atherosclerosis, in which pathogenic macrophages 
accumulate to form plaques on blood vessels. When model mice for atherosclerosis were 
treated with ISP-1/myriocin, a potent biosynthetic inhibitor of sphingolipid biosynthesis, a 
reduction of sphingomyeline, a possible metabolic precursor of SPC, occurred, which was 
coincident with a reduction of atherosclerotic lesions [9]. Although further detailed study is 
needed to conclusively appreciate the physiological and pathological effect of these lipids in 
macrophage production in vivo, the present elucidation of a mechanism involving SPC and 
LSF will provide not only a novel insight into the regulatory mechanisms of monocyte 
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9. FIGURE LEGENDS 
 
 9.1 Fig. 1. Effect of SPC and LSF on TPA-induced marcophagic differentiation. A. B. U937 
cells (A) and THP-1 cells (B) were incubated with S1P (1 M), LSF (5 M), or SPC (10 M) 
for 16 h, followed by treatment with TPA (1 ng/ml) for 72 h. The cells were stained with 
anti-CD11b antibody to determine differentiation into macrophages. Fluorescence intensity 
for anti-CD11b antibody staining was determined by flow cytometry. Similar results were 
obtained in additional sets of experiments (n=3). C. Induction of macrophage markers upon 
TPA plus SPC stimulation. Stimulatory effect of SPC was assessed in a medium containing 
charcoal-treated FBS. Differentiation was induced as A except the cells were overnight 
pretreated with the medium supplied charcoal-treated FBS. During the stimulations, the same 
medium was used. Anti-CD11b or CD206 was used for flow cytometric assessment. Similar 
results were obtained in multiple experiments (n=4). D. U937 cells were differentiated as in A 
and the total RNA was prepared for indicated treatment. Reverse transcribed cDNA was 
assessed for gene expression of the indicated macrophage polarization markers. For IL-10 
and 12 (p40), control template was prepared to assess the sensitivity of PCR conditions used. 
Control templates were serially diluted as indicated. Similar results were obtained in 
duplicate experiments. 
 
9.2 Fig. 2. Effect of SPC and LSF on the Raf/MEK/ERK signaling pathway involved in 
CD11b expression. A. Suppression of the Raf/MEK/ERK signaling pathway by LSF. U937 
cells were preincubated with the indicated concentration of LSF for 16 h and stimulated with 
TPA for 5 min. Cell lysates were prepared as described in the Experimental Procedures. 
Changes in phosphorylation were detected by Western blotting analyses with the indicated 
phosphorylation-dependent and -independent antibodies. B and C. Activation of the 
Raf/MEK/ERK signaling pathway by SPC (B) or S1P (C). U937 cells were starved of serum 
overnight and stimulated with SPC (B) or S1P (C) for the indicated times. Western blotting 
was carried out as in A. D. Effect of the MAP kinase inhibitor on macrophagic differentiation 
in the medium containing charcoal-treated FBS. Flow cytometric analysis for CD11b 
induction was performed as described in the Fig 1C. PD indicates U937 cells pretreated with 
PD98509 for 15 min prior to stimulations by SPC (10 M), followed by treatment with TPA 
(1 ng/ml). Similar result was obtained in duplicated experiment. 
 
9.3 Fig. 3. Inverse effects of SPC and LSF on the PI3K/Akt pathway involved in adhesion to 
fibronectin. A. Effect of SPC and LSF on U937 cell adhesion to fibronectin. Serum-starved 
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U937 cells were transferred to fibronectin-coated 96-well plates and stimulated with the 
indicated concentration of SPC or LSF for 1 h. Non-adherent cells were washed off with 
serum-free medium and the resultant adherent cells were measured by XTT assay as 
described in the Experimental Procedures. Data are shown as the means of triplicate cultures, 
and bars represent standard errors of the mean. B. Activation of the PI3K/Akt signaling 
pathway by SPC. Serum-starved U937 cells were stimulated with SPC for the indicated times. 
Cell lysates were subjected to Western blotting with the indicated antibodies. C. Inhibition of 
SPC-induced adhesion of U937 cells to fibronectin by LY294002, an inhibitor of PI3 
kinase(s). Serum-starved U937 cells were pretreated with LY294002 for 30 min prior to 
stimulation with SPC for 1 h. Cell adhesion was determined as in A. Data are shown as the 
means of triplicate cultures, and bars represent standard errors of the mean. D. Inhibition of 
SPC-induced Akt phosphorylation by LY294002. Serum-starved U937 cells were pretreated 
with LY294002 for 30 min prior to the stimulation with SPC for 5 min. Western blotting was 
carried out as in B. E. Suppression of Akt phosphorylation by LSF. U937 cells were treated 
as described in A. Cell lysates were subjected to Western blotting. Similar results were 
obtained in additional sets of experiments  (n=3). F. Induction of CD11b expression in the 
presence of low concentration of LY249002. U937 cells were differentiated as in Fig.1 C in 
the presence of indicated concentration of LY249002 and CD11b was analyzed by flow 
cytometry. Relative expression of CD11b was calculated as a ratio to the untreated U937 
cells. Similar results were obtained in duplicated experiments.    
 
9.4 Fig. 4. Effect of SPC and LSF on Ca
2+
 influx. A. Induction of Ca
2+
 influx by SPC and 
LSF. Serum-starved U937 cells were loaded with Indo-1 AM (1 M), stimulated with the 
indicated lysosphingolipids, and then further incubated in a time-lapse fluorescent detector to 




]i) as described in the Experimental Procedures. B. 
Failure of S1P to desensitize Ca
2+
 influx induced by SPC or LSF. Desensitization 
experiments were performed as described in A. After initial stimulation with S1P, cells were 
stimulated with the indicated lysosphingolipids. The arrows indicate the time of stimulation. 
Similar results were obtained in additional sets of experiments (n=3).  
 
9.5 Fig. 5. Effects of inhibitors of Gi/o and Gq proteins on the functions of SPC and LSF. A 
and B. SPC (A) and LSF (B) effect on ERK and Akt phosphorylation via Gi/o proteins. 
Serum-starved U937 cells were pretreated with pertussis toxin (PTX) for 16 h prior to 
stimulation with SPC (A) or LSF (B) for 5 min. Cell lysates were subjected to Western 
blotting with the antibodies specific to ERK1/2  and Akt. Similar results were obtained in 
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additional sets of experiments (n=3). C. Effect of Gq inhibitor peptide (Gq-I) on Ca
2+
 
influx induced by SPC or LSF. Serum-starved U937 cells expressing Gq-I were loaded with 
Indo-1 AM (1 M), stimulated with the indicated lysosphingolipids, and then further 
incubated to monitor the change in [Ca
2+
]i.. U937 cells harboring empty vectors were 
employed as a control. Similar results were obtained in an additional set of experiments (n=3). 
D. Effect of Gq-I on LPA2 receptor-mediated calcium influx. Gq-I was introduced to 
LPA2-transfected McA-RH7777 cells with ecotropic MSCV retrovirus vector packaged in 
Plat-E cells. When stimulated with 10 μM LPA, Gq-I infected cells showed attenuated Ca
2+
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11. Legends for supplemental figures 
 
11-1 Supplemental figure 1 
Signal transduction properties of lysosphingolipid response in THP-1 cells 
A. SPC-mediated activation of Raf-Mek-Erk pathway and Akt. THP-1 cells were stimulated 
with SPC and phosphorylation of Raf-Mek-Erk signaling pathway and Akt was examined as 
in Fig 2B and Fig 3B, respectively. Consistent activation was also found in THP-1 cells. B. 
LSF-mediated suppression of Erk1/2 and Akt phosphorylation. THP-1 cells were treated with 
LSF as in Fig 2A and Fig 3E. Consistent reduction of phosphorylation events was also 
detected in THP-1 cells. C. Suppression of SPC-mediated signaling by inhibitor treatment. 
Effect of PTX or LY294002 were assessed in THP-1 cells stimulated with SPC as in Fig 5A. 
Consistently, PTX partially and LY294002 strictly suppressed the phosphorylation of Akt. 
PTX inhibited SPC-induced phosphorylation of ERK1/2. 
 
11-2 Supplemental figure 2 
Retrovirus-mediated expression of HA-Gq inhibitor peptide (Gq-I). U937 cells were 
infected with amphotropic MSCV-IRES-Blasticidin (Vector) or MSCV- Gq-I 
-IRES-Blasticidin and polyclonally selected for 2 weeks. Total RNA was prepared and semi 
quantitative RT-PCR was carried out using a primer set specific to Gq-I. Since Gq-I mini 
gene does not have intronic sequence, amplification was carried out with control experiment 
without reverse transcription. Plasmid DNA of Gq-I retrovirus vector was used for positive 
control. We detected Gq-I expression only on cells with Gq-I infection with reverse 
transcription (HA-GqI). Gq-I -infected U937 cells were prepared in duplicated experiments 
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